Exact Sciences Corporation (EXAS) is focused on further promoting Cologuard as the standard of care. The company prioritizes high-return pipeline opportunities with large patient impacts, which is encouraging. Additionally, the company is advancing digital infrastructure and diagnostics to deliver comprehensive insights at every stage of cancer care. Meanwhile, mounting costs from macroeconomic pressures and overreliance on the Cologuard test raise concerns.In the past year, this Zacks Rank #3 (Hold) stock ...

Exact Sciences Corporation (NASDAQ:EXAS) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 7:30 AM ET Company Participants Kevin Conroy - CEO Aaron Bloomer - CFO Conference Call Participants Vijay Kumar - Evercore Vijay Kumar Great. Thanks everyone for joining us this morning. I'm Vijay Kumar, the Life Sciences and Device Analyst here at Evercore. A pleasure to have with us, the team from Exact Sciences. We have CEO, Kevin Conroy; and CFO, Aaron Bloomer. Kevin, Aaron, thank you for spend ...

Exact Sciences Corporation (NASDAQ:EXAS) Citi's 2024 Global Healthcare Conference December 3, 2024 8:45 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - EVP, Finance Conference Call Participants Patrick Donnelly - Citi Patrick Donnelly Thanks, everybody, for joining us here at the conference. Happy to have Kevin Conroy and Aaron Bloomer from Exact Sciences with us here today. A bunch to cover. There are some QR codes on the table and I think online, I have this iPad up here, see if ...

Exact Sciences Corporation (NASDAQ:EXAS) Citi's 2024 Global Healthcare Conference December 3, 2024 8:45 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - EVP, Finance Conference Call Participants Patrick Donnelly - Citi Patrick Donnelly Thanks, everybody, for joining us here at the conference. Happy to have Kevin Conroy and Aaron Bloomer from Exact Sciences with us here today. A bunch to cover. There are some QR codes on the table and I think online, I have this iPad up here, see if ...

On Monday, the Centers for Medicare & Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule. Included was a final decision related to CMS pricing for Exact Sciences Corp's EXAS Cologuard Plus, a second-generation test that received FDA approval in October. William Blair writes that the determinations effectively raise reimbursement by 16% versus the current Medicare rate for the first-generation Cologuard test (to $592 for Cologuard Plus from $509 for Cologuard) ...

On Monday, the Centers for Medicare & Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule.Included was a final decision related to CMS pricing for Exact Sciences Corp’s EXAS Cologuard Plus, a second-generation test that received FDA approval in October.William Blair writes that the determinations effectively raise reimbursement by 16% versus the current Medicare rate for the first-generation Cologuard test (to $592 for Cologuard Plus from $509 for Cologuard).A ...

Exact Sciences Corporation (NASDAQ:EXAS) Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies Tycho Peterson Thank you both. Kevin, while you're walking up to the podium there, maybe you can talk a little bit about your recent purchase. You bought $1 million worth of stock in the open market. It's a good place to start. Bullish signal. Kevin Conr ...

Exact Sciences Corporation (EXAS) has unveiled data highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of the DETECT-A (Detecting cancers Early Through Elective mutation-based blood Collection and Testing) study, which evaluated a new multi-biomarker class approach, showed improved sensitivity for early-stage and overall cancer detection.The findings from the study were presented at the AACR (American Association of Cancer Research) Special Co ...

Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share releva ...

Key TakeawaysExact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential. Exact Sciences (EXAS) shares plunged Wednesday after the maker of the Cologuard colon cancer screening test reported widening losses and cut its outlook. The company reported a third-quarter net loss of $38.2 million or 21 cents p ...